Clinical trials: Fibrosarcoma NOS
Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors
A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I neurofibromatosis (NF1) (neurofibromas and malignant…
- Trial name
- NCT05011019
- Testing
- AL2846 capsules
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastrointestinal Stromal Tumor, Sarcoma
Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of brostallicin in treating patients who have locally…
- Trial name
- NCT00041249
- Testing
- brostallicin
- Where
- 16 sites in Belgium, France and 3 more
- Volunteers
- 64 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Peripheral Nerve Sheath Tumors
Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or…
- Trial name
- NCT03141021
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 1,050 people
- Sponsor
- Washington University School of Medicine
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Sarcoma
A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
The purpose of the study is to find out if pembrolizumab is a useful treatment that causes few or mild side effects in people with ultra-rare sarcoma.
- Trial name
- NCT07089992
- Testing
- Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase II trial is studying how well imatinib mesylate works in treating patients with locally…
- Trial name
- NCT00085475
- Testing
- imatinib mesylate, conventional surgery
- Where
- 7 sites in Belgium, France and 2 more
- Volunteers
- 17 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Malignant Peripheral Nerve Sheath Tumors
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
This study assesses the safety and efficacy of imatinib mesylate treatment of patients with malignant peripheral nerve sheath tumors
- Trial name
- NCT00427583
- Testing
- imatinib mesylate
- Where
- 2 sites in Germany
- Volunteers
- 11 people
- Sponsor
- Novartis Pharmaceuticals
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor…
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
- Trial name
- NCT03611868
- Testing
- Phase 1b: APG-115+pembrolizumab
- Where
- 21 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Ascentage Pharma Group Inc.
Urachal Cancer, Parathyroid Carcinoma
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors.
- Conditions
- Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma
- Trial name
- ANTARES (NCT06638931)
- Testing
- Nivolumab
- Where
- 5 sites in Brazil
- Volunteers
- 28 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors
Trial of Dasatinib in Advanced Sarcomas
This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.
- Conditions
- Rhabdomyosarcoma, Malignant Peripheral Nerve Sheath Tumors, Chondrosarcoma, Sarcoma, Ewing's
- Trial name
- NCT00464620
- Testing
- Dasatinib
- Where
- 20 sites in United States
- Volunteers
- 366 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Sarcoma
Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00030784
- Testing
- ifosfamide, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 28 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Malignant Neoplasms
A Study of DEG6498 in Participants With Solid Tumors
The goal of this first in human, Phase 1, multi-center, open-label, and 2-part study is to learn whether DEG6498 is safe and tolerable in participants with advanced solid tumors.
- Trial name
- NCT07244835
- Testing
- DEG6498
- Where
- 3 sites in China
- Volunteers
- 100 people
- Sponsor
- Degron Therapeutics Co.
Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
This is a phase 1, open-label, single centre study of investigational drug selinexor in participants with soft tissue sarcomas that cannot be treated with standard therapies.
- Conditions
- Soft Tissue Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Leiomyosarcoma, Endometrial Stromal Sarcoma
- Trial name
- NCT04811196
- Testing
- Selinexor
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
Sarcoma
Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- VORTEX (NCT00423618)
- Testing
- radiotherapy
- Where
- 6 sites in United Kingdom
- Volunteers
- 216 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed…
- Conditions
- Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma
- Trial name
- NCT03009201
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with surgery and/or radiation therapy may kill more tumor cells.
- Trial name
- NCT00002898
- Testing
- dactinomycin, carboplatin, cyclophosphamide
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- Societe Internationale d'Oncologie Pediatrique
Leiomyosarcoma, Liposarcoma
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
- Conditions
- Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma
- Trial name
- NCT06277154
- Testing
- MASCT-I, Doxorubicin, Ifosfamide
- Where
- China
- Volunteers
- 148 people
- Sponsor
- HRYZ Biotech Co.